ClinOne and Boston Children’s Hospital partner for trial enhancement

11th November 2019 (Last Updated December 24th, 2019 06:52)

ClinOne has launched its eConsent with Video eConsent technology in collaboration with Boston Children’s Hospital (BCH).

ClinOne has launched its eConsent with Video eConsent technology in collaboration with Boston Children’s Hospital (BCH).

The technology is rolled out within Boston Children’s pulmonary research team to evaluate its further use sitewide.

ClinOne said that its eConsent programme will offer initial, re-consent and remote consent capabilities from any location.

It could later become available to BCH’s 400 clinical trials currently being undertaken.

The latest technology also simplifies and organises the informed consent process for research teams, investigators, and study patients. It reduces the on-site consenting obstacles.

It also decreases delays between updated consent documents and re-consenting needs.

During the consent process, the video consent technology is designed to stream both audio and video recordings of live interactions between clinical study participants and research staff in real-time.

The technology enables patients and research staff to conduct various activities, such as study discussion, consent document review and signature process completion at their current location.

A key feature of Video eConsent technology is that it makes timely delivery of crucial information by research members possible. This allows participants and their family members and caregivers in informed decision-making and to provide approvals from their homes.

Boston Children’s Hospital CEO Sandra Fenwick said: “For 150 years, families have come from around the corner and across the world looking to Boston Children’s for answers.

“This is the place where the most difficult challenges are faced head-on, where the impossible becomes possible, and where families in search of answers find them.

“We hope that by their addition of ClinOne’s eConsent solution, these needs and challenges can be met for clinical trial participants even more successfully.”